Study: Heart transplantation is a very safe and effective therapy

Heart transplantation is a very safe and effective therapy, according to a new long-term study presented today at the Canadian Cardiovascular Congress 2011, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

Researchers at the University of Ottawa Heart Institute heart transplant program revealed results from 25 years of follow-up on a total of 461 transplant patients. Mean age at transplant was 49 -13 years. Patients were followed and managed according to guidelines in effect at the time.

They found that survival rates have improved by more than 20 per cent over the years since modern heart transplantation became available in 1980.

"Heart transplants are amazingly effective therapy," says Dr. Marc Ruel, surgical director of the heart transplant program at the University of Ottawa Heart Institute. "We must remember that half of these patients would otherwise not have lived one year without a transplant."

The Heart Institute found that survival rates have been good over the years, especially from 2003 onward, with more advanced surgical and medical care, where the survival rate at eight years post-surgery is now 89.3 per cent. "Results have significantly improved over the years," says Dr. Ruel.

The study found that overall survival rates for the 25-year period were:

  • At one year - 86%
  • At five years - 75%
  • At 10 years - 62%
  • At 15 years - 47%
  • At 20 years - 36%

Fifty-five per cent of all patients were status 3 or higher - meaning they had more complicated and urgent medical needs - at transplant.

Survival was negatively influenced by age at transplant. The younger the patient is at the time of transplant, the more successful the outcome. Each additional 10 years of age decreases the survival rate by 20 per cent, the study found.

Survival was not significantly affected by gender or by whether a patient was on a ventricular assist device − a mechanical pump that helps a weakened heart pump blood throughout the body − pre-transplant.

Causes of death beyond the perioperative period were cardiac allograft vasculopathy in 36 per cent (at a mean of eight years post-transplant), rejection in six per cent (at a mean 1.4 years post-transplant), sepsis in 10 percent (at a mean of one year post-transplant), cancer in 17 per cent (at a mean of 7.7 years post-transplant), and other causes in 32 per cent (at a mean of 8.2 years post-transplant).

Successful heart transplantation is a team effort that starts with donor identification, consent from families, donor preparation, and collaboration between hospitals. It involves a large team of surgeons, transplant cardiologists, nurses, coordinators, physiotherapists, and social workers.

"Heart transplant is one of the most philosophically, symbolically, surgically and medically beautiful acts," says Dr. Ruel. "Although the number of donors will always be insufficient until we find new therapies such as cardiac regeneration, it is important to recognize the importance of heart transplant programs and of organ donation, in light of the many lives saved and families positively touched by this therapy. We hope that this research conveys the message."

"Heart transplant is a very good choice for some patients," adds Dr. Haissam Haddad, medical director of the University of Ottawa Heart Institute heart transplant program. "It has a strong record of safety and success."

Heart disease is a leading cause of death in Canada. "Heart transplantation is an excellent treatment to the select few who need it," says Heart and Stroke Foundation spokesperson Dr. Beth Abramson. "We can all do our part by signing our donor cards and letting loved ones know our wishes." She also recommends we all lead healthy lives to try to prevent heart disease.

"Canadians with heart failure who otherwise might have died have access to a life-saving procedure thanks to generous donors and our incredible multidisciplinary transplant teams," says Dr. Abramson. "This research is a valuable measure of how this life-saving advance is working for our sickest patients - those who need a new heart."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure